ACRV Stock — Acrivon Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing our proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform designed to quantify compound-specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.61

Market cap

$69.0M

Cash

$90.0M

Enterprise value

-$21.0M

Balance sheet

Cash	$90.0M
Debt	$0.0M
Net cash	$90.0M
Enterprise value	-$21.0M
Basic shares	42.9M shares
Fully diluted shares	53.3M shares
Fully diluted market cap	$85.8M
Cash per share	$2.10
Quarterly burn	$14.9M
Cash runway	6.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

42.9M

Pre-funded warrants

0.0M

Options

8.1M

RSUs

1.0M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

1.3M

FDSO

53.3M

Cap table as of 2026-06-30.

Price history

Loading ACRV daily closes…

Loading price history…

Next catalyst

ACR-368 · Est. Nov 7, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	ACR-368 Phase 2b in serous endometrial cancer, prespecified interim analysis and data update · NCT05548296	Phase 2b	serous endometrial cancer	H2 2026
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	CDK11 inhibitor IND filing to FDA for development candidate	Not disclosed	development candidate	H1 2027
Jul 11 - Aug 22 in 8 mo	ACR-368	Phase 2	Endometrial Adenocarcinoma	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ACR-368

Phase 2 · Active Modality: small molecule inhibitor

Aliases prexasertib

Target CHK1/2

Partnerships In-licensed from Eli Lilly and Company; OncoSignature companion test performed by Akoya (CLIA lab) under agreement

Indications

Endometrial cancer (EC) (Phase 2)
Squamous cell carcinoma of head and neck (SCCHN) (Phase 2)

Catalysts

— second half of 2026

Status note Phase 2b registrational-intent study; lead program. SCCHN indication evaluated in an investigator-initiated trial (IIT). Received FDA Fast Track designation for ACR-368 monotherapy based on OncoSignature-predicted sensitivity. Earlier Lilly-sponsored Phase 2 included platinum-resistant ovarian cohorts, but the current program focuses on EC.

ACR-2316

Phase 2 · Active

Target WEE1/PKMYT1

Indications

Small cell lung cancer (SCLC) (Phase 2)
Squamous non-small cell lung cancer (sqNSCLC) (Phase 2)
Adenocarcinoma non-small cell lung cancer (adNSCLC) (Phase 2)

Status note Filing describes a Phase 1/2 study (dose escalation complete, two weekly dosing regimens established) now in the dose-expansion stage in AP3-identified, molecularly defined tumors. Second clinical-stage asset.

CDK11 program

Preclinical · Active

Target CDK11

Status note Internally discovered development candidates toward planned IND filing; discovered via AP3 co-crystallography platform. IND-enabling studies being initiated.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	ACR-368
Lead indication	Endometrial Adenocarcinoma
Lead phase	Phase 2
Active trials	2
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05548296	Phase 2	Recruiting	Sponsor	Acrivon Therapeutics	—	Endometrial Adenocarcinoma	H2 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)
NCT06667141	Phase 1	Recruiting	Sponsor	Acrivon Therapeutics	—	Specific Advanced Solid Tumors	—
NCT06597565	Phase 2	Recruiting	Collaborator	H. Lee Moffitt Cancer Center and Research Institute	—	Head and Neck Squamous Cell Carcinoma	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Acrivon Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
RA Capital Management	12,229,396	+3,888,888	0.19%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ACRV — Acrivon Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

ACRV — Acrivon Therapeutics Inc.